💊
Tepmetko
tepotinib
Carcinom, pulmonar non-microcelular
✅ Autorizat
✅
Nu există alerte active
Acest medicament nu are penurii în curs, scrisori de siguranță sau retrageri de pe piață.
La ce se utilizează
Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
⚠️ Siguranță a pacientului
No
Pagina oficială EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko